Treatment of depression

Abstract

There is described a compound selected from the group consisting of tramadol, resveratrol, acetaminophen, xorphanol, cinfenoac, furcloprofen, bismuth subsalicylate, enofelast, triflusal, ketorfanol, indriline, furofenac, cizolirtine, dacemazine, demelverine, and fenethazine, and derivatives and / or combinations thereof, for the treatment or alleviation of depression.

Description

technical field [0001] The invention provides medicine and method for treating depression. Background technique [0002] According to the latest research from the World Health Organization, depression ranks among the 10 leading causes of disability. Research by WHO predicts that by 2020 depression will become the second leading cause of the world's health burden (WHO 2001). Currently, more than 120 million people suffer from depression and need treatment for depression. Many people are afflicted by depression at some point in their lives: WHO estimates that a total of 17% of men and women will suffer from depression during their lifetime. Women suffer from depression more often than men. In total, an estimated 6 percent of men and 9.5 percent of women will experience depression at any given age. [0003] It is also estimated that many people who actually suffer from depression are not clinically correctly diagnosed with depression. It is estimated that only about 40% of...

AI Technical Summary

Problems solved by technology

In a fifth example, the sensory input system is normal, but the system responsible for sensing pain and the central emotional system are both dysfunctional and output inappropriate depressive behavior

Images